Australia markets closed

Kiora Pharmaceuticals, Inc. (7EY0.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.4370-0.0320 (-6.82%)
As of 09:24AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 12.56M
Enterprise value 10.37M
Trailing P/E 0.71
Forward P/E 1.86
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.46
Price/book (mrq)2.16
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.84

Trading information

Stock price history

Beta (5Y monthly) -0.26
52-week change 3-80.00%
S&P500 52-week change 322.38%
52-week high 32.4650
52-week low 30.4000
50-day moving average 30.5155
200-day moving average 30.5001

Share statistics

Avg vol (3-month) 3581
Avg vol (10-day) 3N/A
Shares outstanding 526.26M
Implied shares outstanding 626.78M
Float 817.28M
% held by insiders 10.86%
% held by institutions 126.37%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:40
Last split date 327 Sept 2022

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-33.54%
Return on equity (ttm)-142.88%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -8.64M
Net income avi to common (ttm)-13.04M
Diluted EPS (ttm)-2.5100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.45M
Total cash per share (mrq)0.09
Total debt (mrq)106.89k
Total debt/equity (mrq)1.75%
Current ratio (mrq)2.90
Book value per share (mrq)0.79

Cash flow statement

Operating cash flow (ttm)-9.56M
Levered free cash flow (ttm)-6.77M